Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elsamitrucin in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00090090Phase 2Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elsamitrucin in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoints: Safety and Efficacy and Efficacy in NHL subtypes. Started Apr 2004; status: completed.
02
Drugs
elsamitrucin
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00090090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090090.